Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
COSCIENS Biopharma ( (TSE:CSCI) ) has issued an announcement.
On May 13, 2025, COSCIENS Biopharma Inc. reported its financial results for the first quarter of 2025, highlighting a strategic repositioning as a natural-based product company. The company announced the advancement of its Phase 2 clinical trial for Avenanthramide tablets and the appointment of Anna Biehn as CEO. Despite a net loss increase to $3.7 million due to higher operating expenses, COSCIENS is focused on cost-cutting measures and leveraging its PGX technology for commercial production. The company’s nutraceutical portfolio expansion includes the development of Oat Beta Glucan and Yeast Beta Glucan products, aiming to address wellness and immune-boosting needs.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a life sciences company that develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical, and pharmaceutical products. The company utilizes proprietary extraction technology to produce active ingredients from renewable plant resources, which are used in skincare products and are being developed as potential nutraceuticals and pharmaceuticals. COSCIENS also offers Macrilen®, an FDA and EMA approved oral test for diagnosing adult growth hormone deficiency.
Average Trading Volume: 2,116
Technical Sentiment Signal: Sell
Current Market Cap: C$14.5M
For a thorough assessment of CSCI stock, go to TipRanks’ Stock Analysis page.